BlackRock
BDTX icon

BlackRock’s Black Diamond Therapeutics BDTX Stock Holding History

BlackRock’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.25M Buy
3,917,088
+2,810,248
+254% +$6.87M ﹤0.01% 3811
2026
Q1 		$2.36M Buy
1,106,840
+218,580
+25% +$520K ﹤0.01% 4087
2025
Q4 		$2.16M Sell
888,260
-139,832
-14% -$495K ﹤0.01% 4095
2025
Q3 		$3.9M Sell
1,028,092
-62,771
-6% -$184K ﹤0.01% 3876
2025
Q2 		$2.71M Sell
1,090,863
-2,381,893
-69% -$4.59M ﹤0.01% 3981
2025
Q1 		$5.38M Sell
3,472,756
-46,389
-1% -$97.3K ﹤0.01% 3622
2024
Q4 		$7.53M Buy
3,519,145
+21,379
+0.6% +$61.3K ﹤0.01% 3559
2024
Q3 		$15.2M Buy
3,497,766
+280,638
+9% +$1.53M ﹤0.01% 3198
2024
Q2 		$15M Buy
3,217,128
+1,836,606
+133% +$9.86M ﹤0.01% 3149
2024
Q1 		$7M Buy
1,380,522
+30,475
+2% +$123K ﹤0.01% 3534
2023
Q4 		$3.79M Sell
1,350,047
-50,058
-4% -$117K ﹤0.01% 3801
2023
Q3 		$4.02M Sell
1,400,105
-105,334
-7% -$388K ﹤0.01% 3738
2023
Q2 		$7.6M Buy
1,505,439
+749,052
+99% +$1.53M ﹤0.01% 3543
2023
Q1 		$1.43M Sell
756,387
-237,382
-24% -$545K ﹤0.01% 4204
2022
Q4 		$1.79M Sell
993,769
-269,748
-21% -$486K ﹤0.01% 4180
2022
Q3 		$2.14M Sell
1,263,517
-8,595
-0.7% -$26.5K ﹤0.01% 4166
2022
Q2 		$3.13M Sell
1,272,112
-1,057,052
-45% -$2.46M ﹤0.01% 4035
2022
Q1 		$6.45M Buy
2,329,164
+80,697
+4% +$295K ﹤0.01% 3817
2021
Q4 		$12M Buy
2,248,467
+57,837
+3% +$404K ﹤0.01% 3564
2021
Q3 		$18.5M Buy
2,190,630
+36,418
+2% +$360K ﹤0.01% 3328
2021
Q2 		$26.3M Buy
2,154,212
+223,627
+12% +$4.42M ﹤0.01% 3132
2021
Q1 		$46.8M Buy
1,930,585
+257,447
+15% +$6.94M ﹤0.01% 2661
2020
Q4 		$53.6M Buy
1,673,138
+575,818
+52% +$18.9M ﹤0.01% 2424
2020
Q3 		$33.2M Buy
1,097,320
+344,952
+46% +$10.5M ﹤0.01% 2539
2020
Q2 		$31.7M Buy
752,368
+184,680
+33% +$6.8M ﹤0.01% 2541
2020
Q1 		$14.2M Buy
+567,688
New +$17.3M ﹤0.01% 2796

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

BlackRock's BDTX Position: Q2 2026 in Review

BlackRock increased its Black Diamond Therapeutics (BDTX) stake by 254% in Q2 2026, buying an estimated $6.87M and bringing the position to 3,917,088 shares worth $7.25M. The position accounts for ﹤0.01% of the portfolio, ranked #3811.

BlackRock first reported a position in BDTX in Q1 2020 and has held it in 26 quarters since. The position peaked at $53.6M in Q4 2020. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • BlackRock held 3,917,088 shares of Black Diamond Therapeutics worth $7.25M as of Q2 2026.
  • BlackRock bought 2,810,248 Black Diamond Therapeutics shares in Q2 2026, an estimated $6.87M.
  • Black Diamond Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3811 holding.
  • BlackRock first reported a position in Black Diamond Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • BlackRock's Black Diamond Therapeutics position peaked at $53.6M in Q4 2020.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.